WASHINGTON, DC, Oct. 4 – Fledgling microfluidic firm BioMicro said on Thursday that it hopes to close a Series B round of financing worth $10 million by the end of the year.

Michael McNeely, president and CEO of the Sandy, Utah-based company, told GenomeWeb that the capital will help BioMicro commercialize its novel microfluidics platform, the Micro Array User Interface, or MAUI.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.